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evidence from in vitro and in vivo studies has demonstrated that DPPIV cleaves the N-terminal dipeptide from intact BNP , yielding BNP , 3 which displays remarkably reduced renal and vascular activities. 12 Thus, one of the possible mechanisms for the development of natriuretic peptide resistance in HF is the increased inactivation of BNP (1-32) mediated by enhanced catalytic activity of DPPIV. To date, however, the hypothesis that DPPIV activity is increased in HF remains untested.
In this context, the present study tested the hypothesis that circulating DPPIV activity is increased and associated with adverse cardiovascular outcomes in patients and in a rat model of experimental HF. The potential use of the DPPIV inhibitor sitagliptin for preventing cardiac dysfunction and the possibility that the effect of DPPIV inhibition is, at least in part, mediated by cardiac GLP-1 receptor stimulation were also investigated.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Selection of Patients With HF
All patients signed an informed consent form, and the study was approved by the Ethics Committee of the Heart Institute of the University of São Paulo, São Paulo, Brazil. One hundred ninety patients with HF from an ongoing inception cohort from the General Outpatient Clinic of the Heart Institute of University of São Paulo were included in this study. The ascertainment period was from 2005 to 2010. After enrollment, the serum samples were frozen at −80°C until analysis.
Animal Protocols, Surgical Procedures, and Drug Treatment
Experimental procedures were conducted in accordance with the guidelines established by the Brazilian College for Animal Experimentation and approved by the institutional animal care and use committee. Experimental HF was induced in male Wistar rats (200-250 g; n=58) via left ventricular (LV) myocardial injury using radiofrequency catheter ablation, as previously described. 13 Sham-operated rats underwent left thoracotomy and were mock ablated (n=20).
Determination of DPPIV Activity and Abundance
DPPIV activity was assayed by measuring the release of p-nitroaniline resulting from the hydrolysis of glycylproline p-nitroanilide tosylate, as previously described. 14 The abundance of DPPIV was evaluated by immunoblotting.
Evaluation of Cardiac Function
Hemodynamic assessment was performed using a pressure-volume conductance catheter, as previously described.
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Determination of the Plasma Concentrations of Active GLP-1 and Total BNP
The plasma levels of intact GLP-1 (7-36 amide) and total BNP were measured using ELISAs from Linco Research (St. Charles, MO) and Bachem (Torrance, CA), respectively, in accordance with the manufacturer's instructions.
Statistical Analysis
Data are expressed as the mean±SEM unless stated otherwise. For each data set, the Levene test was performed to examine the homogeneity of variances. If Levene test revealed unequal variance, then Welch ANOVA was used. If variance was equal, then a Student t test or 1-way ANOVA followed by Bonferroni post hoc tests was performed. The relationships between the plasma DPPIV activity and the parameters of HF were assessed by Pearson correlation test. P<0.05 was considered statistically significant.
Results
Circulating DPPIV Activity in Patients with HF
The general demographic characteristics of the studied population are shown in Table I in the online-only Data Supplement. In the patients with HF, the measured DPPIV activity followed a normal distribution ( Figure 1A ). The mean (±SD) serum DPPIV activity in the 190 selected patients with HF was significantly higher than that of the normal subjects (n=42; P<0.001; Figure 1B) . A significant negative correlation was found between serum DPPIV activity and LV ejection fraction in patients with HF (r=−0.20; P=0.009). Interestingly, we also observed statistically significant correlations between serum DPPIV activity and age (r=−0.19; P=0.02), serum sodium (r=0.22; P=0.004), hemoglobin (r=0.20; P=0.01), and triglycerides (r=0.23; P=0.005) ( Figure I in the online-only Data Supplement). The serum DPPIV activity in patients with HF did not significantly correlate with body weight index, heart rate, systolic or diastolic blood pressure, serum potassium, total cholesterol, serum creatinine, or serum glucose (data not shown). Circulating dipeptidyl peptidase IV (DPPIV) activity in patients with heart failure (HF) and normal subjects. A, Frequency distribution of serum DPPIV activity from 190 patients with HF and 42 control subjects without cardiovascular disease. In both groups, serum DPPIV activity exhibited a Gaussian distribution. B, Average serum DPPIV activity in patients with HF and control subjects. The values are the means±SD. ***P<0.001 vs control.
Experimental Model, Biometric and Cardiac parameters
Radiofrequency LV ablation-induced HF rats 13 displayed typical cardiac dysfunction, including elevated LV end-diastolic pressure and time constant of relaxation, with decreased dP/dt, ejection fraction, cardiac output, and stroke work, although there was no change in the heart rate (Table) . The indexed lung mass and the percent of water content were significantly elevated in the HF animals compared with the sham group (Table) , suggesting that our experimental model of LV ablation-induced HF exhibited pulmonary congestion secondary to cardiac decompensation. Figure 2 demonstrates that rats with HF displayed higher DPPIV activity in the plasma (Figure 2A ) and heart ( Figure 2B ) compared with sham animals. The average plasma DPPIV activity in radiofrequency LV-ablated rats treated with 40 mg/kg BID sitagliptin for 6 weeks was 6.77±1.05 nmol/mL per minute, which corresponded to ≈90% inhibition compared with HF rats and 85% inhibition compared with sham rats (Figure 2A ). Moreover, treatment with sitagliptin significantly inhibited DPPIV heart activity in HF rats ( Figure 2B ). In agreement with the pattern of enzymatic activity, the abundance of DPPIV, as assessed by immunoblotting, increased both in the plasma ( Figure 2C ) and in the heart ( Figure 2D ) from the HF rats compared with the sham rats. As depicted in Figure 2C and 2D, sitagliptin not only inhibited DPPIV catalytic activity but also decreased the abundance of the enzyme both in plasma and heart.
Determination of DPPIV Activity and Abundance in Sham-Operated and Experimental HF Rats Treated or Not With the DPPIV Inhibitor Sitagliptin
To determine in which cardiac cell type the upregulation of DPPIV expression occurred, heart sections were analyzed by immunofluorescence using specific cell markers. As demonstrated in Figure 2E , costaining for von Willebrand factor with DPPIV indicated that upregulated DPPIV expression was confined to the surface of heart endothelial cells. Though the kidney is the principal site of expression of DPPIV, 16 no significant differences were found in renal cortical DPPIV activity and expression between sham and HF rats ( Figure IIA and IIB in the online-only Data Supplement).
Correlation of Plasma DPPIV Activity With Cardiac Dysfunction and Congestion
Similar to what was observed in patients with HF, there were significant correlations between plasma DPPIV activity and different parameters of cardiac dysfunction and congestion in the rat model of HF ( Figure 3 ). Plasma DPPIV activity correlated negatively with LV ejection fraction (Pearson r=−0.70; P<0.01; Figure 3A ) and positively with LV end-diastolic pressure (Pearson r=0.72; P<0.001; Figure 3B ) and with the lung/ body weight index (Pearson r=0.78; P<0.001; Figure 3C ).
Effect of DPPIV Inhibition on the Cardiac Function of Experimental HF Rats
The rats that were treated with the DPPIV inhibitor exhibited significant attenuation of HF-related dysfunction and Values are means±SEM. +dP/dt max and -dP/dt max indicate maximal rate of LV pressure increment and decrement, respectively; BW, body weight; CO, cardiac output; DPPIV, dipeptidyl peptidase IV; EDV, end-diastolic volume; EF, ejection fraction; HF, heart failure; HR, heart rate; LVEDP, LV end-diastolic pressure; LVSP, left ventricular (LV) systolic pressure; MAP, mean arterial pressure; SV, stroke volume; SW, stroke work; TPR, total peripheral resistance; and τ, time constant of LV pressure decay.
*P<0.05 and **P<0.01 vs sham; #P<0.05 and ##P<0.01 vs HF.
remarkably mitigated pulmonary congestion (Table and Figure 4 ). . Dipeptidyl peptidase IV (DPPIV) activity and expression in the plasma and heart of a rat model of chronic heart failure (HF). DPPIV activity in (A) plasma and (B) heart membrane proteins from radiofrequency left ventricular (LV) ablation-induced HF rats treated with the DPPIV inhibitor sitagliptin (HF+IDPPIV) or not (HF) and sham rats. C, An equal volume of plasma (0.5 µL) from each animal was subjected to SDS-PAGE, transferred to polyvinylidene fluoride membranes and incubated with an antibody against DPPIV. The membranes were stained with Ponceau S before antibody incubation, and albumin was used as an internal control. D, Equal amounts of protein (50 µg for DPPIV and 2.5 µg for actin) from the heart membrane fractions isolated from sham or HF rats were subjected to immunoblotting for DPPIV and actin; the latter was used as an internal control. The values are the means±SEM. The number of animals analyzed in each group is indicated within the bar. **P<0.01 and ***P<0.001 vs sham; #P<0.05 and ###P<0.001 vs HF. E, Representative images of the heart sections from radiofrequency LV ablation-induced HF rats (HF) and sham rats costained with antibodies against DPPIV (red) and the endothelial cell marker von Willebrand factor (green). The scale bar is 20 μm.
between the end-systolic volumes and pressures of the radiofrequency LV-ablated rats treated with the DPPIV inhibitor sitagliptin was similar to that of the sham rats ( Figure 4D , left). In addition, the increased slope of the end-diastolic pressurevolume relationships in the HF group compared with the sham group, which is suggestive of increased chamber stiffness, was significantly mitigated by DPPIV inhibition ( Figure 4D , right).
Cardioprotective Effects of DPPIV Inhibition in Experimental HF Rats
The cardiac mass and volume are presented in the Table. Although body weight was similar among the groups, the heart weight as a function of body weight was significantly increased in the HF rats. This finding was associated with ventricular dilation (ie, increased end-diastolic volume), suggesting the occurrence of cardiac remodeling. These parameters were partially preserved by sitagliptin treatment. Histological analysis of the remodeled myocardium far from the scar demonstrated a significant increase in the average cardiomyocyte nuclear volume in the HF rats compared with the sham rats, which was significantly reduced by DPPIV inhibition ( Figure 5A ). In addition, the increased interstitial collagen in reminiscent tissues evidenced in the HF group was significantly attenuated by sitagliptin treatment ( Figure 5B ) compared with samples from similar regions. As depicted in Figure 5C, 
Effect of DPPIV Inhibition on GLP-1 Circulating Level, on Heart GLP-1 Receptor Expression, and on the Stimulation of Cardioprotective Signaling Pathways
The plasma level of active GLP-1 was 3.2 times greater in the sitagliptin-treated radiofrequency LV-ablated rats than in the HF animals and 2.4 times greater than in the sham rats ( Figure 6A ). Additionally, there was a significant decrease in plasma GLP-1 in HF rats (≈25%) compared with the sham rats ( Figure 6A ). The level of the GLP-1 receptor in the heart was examined using immunoblotting and normalized to actin. As depicted in Figure 6B , the GLP-1 receptor was significantly more abundant in the HF rats than in the sham rats (118±21%, P<0.05). Sitagliptin remarkably increased cardiac GLP-1 receptor expression compared with the sham rats (180±28%, P<0.01) and with the HF rats (63±5%, P<0.05). The signaling pathways transduced downstream of the cardiac GLP-1 receptor were examined using ELISA and immunoblotting. Sitagliptin treatment increased cardiac protein kinase A activity compared with HF and sham rats, suggesting the activation of the cAMP-protein kinase A pathway ( Figure 6C) .
Similarly, the ratio of phosphorylated to total Akt (114±27%, P<0.01) increased in the hearts of the sitagliptin-treated radiofrequency LV-ablated rats compared with the HF rats and (104±30%, P<0.01) compared with the sham rats (Figure 6D) . The expression of B-cell CLL/lymphoma 2 (Bcl-2) and Bax (Bcl-1-associated X protein), apoptosis-related proteins downstream of Akt, were also examined ( Figure 6E ). Cardiac Bcl-2 expression was decreased in HF rats relative to sham (70±4%, P<0.001) and to sitagliptin-treated radiofrequency LV-ablated rats (42±2%, P<0.05). Conversely, Bax expression was increased in the heart of HF rats relative to sham (126±13%, P<0.01) and to sitagliptin-treated radiofrequency LV-ablated rats (36±3%, P<0.05). Consistent with the data shown in Figure 5C , the Bcl-2 to Bax ratio was decreased in HF rats compared with sham, and this reduction was significantly mitigated by treatment with sitagliptin.
Effect of DPPIV Inhibition on Total BNP Circulating Level, on Kidney Function, and on the Stimulation of Renoprotective Signaling Pathway
Plasma total BNP was greater in the HF rats than in the sham rats and the radiofrequency LV-ablated rats treated with sitagliptin ( Figure 7A ). Despite the higher circulating total BNP, renal protein kinase G activity was lower in HF rats compared with sham rats (28±3%, P<0.05) and with sitagliptin-treated radiofrequency LV-ablated rats (53±5%, P<0.001; Figure 7B ). As previously shown, 15 sodium ( Figure 7D ), and glomerular filtration rate ( Figure 7E) were not significantly different between HF and sham rats. Treatment with sitagliptin did not alter urinary flow or fractional sodium excretion compared with sham and HF rats. However, as shown in Figure 7E , glomerular filtration rate was modestly but significantly increased by sitagliptin compared with HF rats.
Discussion
The present work demonstrated that circulating DPPIV activity correlates with poorer cardiovascular outcomes in human and experimental HF. The upregulation of DPPIV activity and expression are increased on the surface of heart cells in HF rats, particularly endothelial cells, suggesting that this peptidase may be directly involved in cardiac dysfunction. Furthermore, we determined that treating radiofrequency LV-ablated rats with the DPPIV inhibitor sitagliptin significantly attenuates HF-related cardiac remodeling and dysfunction. The cardioprotective effects of DPPIV inhibition seem to be partially attributed to increased GLP-1 bioavailability and stimulation of the cardiac GLP-1 receptor. These results confirm and extend accumulating evidence that the inhibition of DPPIV ameliorates cardiac function in experimental models of cardiovascular disease. Enhanced serum or plasma DPPIV activity has been noted in patients with cardiovascular and metabolic diseases such as type 1 and 2 diabetes mellitus, 17, 18 obesity, 19 and pulmonary hypertension. 20 This work demonstrated that circulating DPPIV activity is increased in patients with HF and in radiofrequency LV ablation-induced HF rats. The higher DPPIV activity observed in HF suggests that this condition may involve greater degradation of a wide range of DPPIV substrates that possess cardioactive, vasoactive, and renal effects. The reduced bioavailability of these molecules after myocardial injury may lead to HF aggravation and decompensation. Accordingly, in addition to the fact that DPPIV-knockout mice exhibit increased survival after experimental myocardial infarction, 21 our observation that DPPIV correlates with Figure 6 . Effects of dipeptidyl peptidase IV (DPPIV) inhibition on glucagon-like peptide-1 (GLP-1) circulating level, GLP-1 receptor expression in the heart and the activation of cardioprotective signaling pathways. A, Circulating active GLP-1 (7-36) was measured using ELISA in sham, radiofrequency LV ablation-induced heart failure rats (HF), and LV-ablated rats treated with sitagliptin for 6 weeks (HF+IDPPIV). B, Representative immunoblots and graphical representation of heart membrane proteins isolated from sham rats, HF rats, or HF+IDPPIV rats probed with an antibody against the GLP-1 receptor. C, protein kinase A (PKA) activity was measured by ELISA. D and E, Representative immunoblots and graphical representation of heart membrane proteins from the 3 groups of rats probed with (D) antibodies against phosphorylated Akt (pAkt) and total Akt and (E) antibodies against Bcl-2 and Bax. Antiactin was used as an internal control. The values are the means±SEM. n=6 rats/group. *P<0.05, **P<0.01, and ***P<0.001 vs sham. #P<0.05 and ###P<0.001 vs HF.
poorer cardiovascular outcomes in patients and in a rat model further substantiates the potential therapeutic benefits of DPPIV inhibition in HF. Long-term treatment of radiofrequency LV-ablated rats with sitagliptin increased circulating active GLP-1 by ≈3-fold. It is surprising to note that the hearts of radiofrequency LV-ablated rats treated with sitagliptin expressed significantly higher levels of the GLP-1 receptor compared with the sham and HF rats. Taken together, these findings suggest that enhanced coupling of GLP-1 to its cardiac receptor may occur, and this enhanced coupling may represent one possible mechanism underlying the observed sitagliptin-induced cardioprotection after radiofrequency myocardial injury. Accordingly, we observed that the cardioprotective signaling pathways transduced downstream of the GLP-1 receptor, 7 including protein kinase A, Akt, and the antiapoptotic protein Bcl-2, were activated by sitagliptin treatment.
Several independent lines of evidence from both animal and human studies indicate that GLP-1, 8, 22, 23 GLP-1 analogs, 24 and GLP-1 receptor agonists 23, 25 exert cardioprotective benefits in HF. However, far fewer studies have examined the role of DPPIV inhibition in preventing or reversing HF. The administration of sitagliptin (30 mg/kg per day) to pigs with pacinginduced HF improved their LV hemodynamics, reduced their heart rate, and preserved their renal function. 26 Conversely, the administration of the DPPIV inhibitor vildagliptin (15 mg/ kgper day) to rats either before or after myocardial infarction did not prevent or reverse HF-related cardiac dysfunction. 27 In line with those findings in pigs, we discovered that the administration of sitagliptin (40 mg/kg BID) to radiofrequency LV-ablated rats has a protective effect on LV hemodynamic function. Of note, those 2 previous studies and ours differ in terms of the dose of the DPPIV inhibitor used, the frequency of administration, and how the inhibitors were orally administered (drinking water versus gavage). Thus, as mentioned, 27 the lack of vildagliptin-induced cardioprotection in rats with postmyocardial infarct-induced HF may be attributable, at least, in part, to the low dosage used. The use of a low dose produced a lower level of circulating DPPIV inhibition compared with our study (≈70% versus 90%) and possibly a lower level of enzyme catalytic inhibition on target tissues, such as the heart, blood vessels, and kidneys, where the DPPIV substrates exert their protective actions.
The findings that serum DPPIV activity correlates with serum sodium level in patients with HF and with lung congestion in HF rats imply that higher DPPIV activity results in worse cardiovascular outcomes in human and experimental HF. Of note, we previously discovered that DPPIV physically 28 and functionally 29, 30 interacts with the Na + /H + exchanger isoform 3 (NHE3), the major apical transcellular pathway for sodium reabsorption in the renal proximal tubule. Our group also determined that NHE3-mediated sodium reabsorption increased in the proximal tubule of rats with HF, 15 which may contribute to lower sodium and water excretion, extracellular volume expansion, and peripheral and pulmonary edema. Enhanced NHE3 transport activity may also diminish the sodium delivery to the distal nephron, thus conferring resistance to the natriuretic actions of BNP in patients and experimental models of HF. Inhibitors of DPPIV, 29, 30 native GLP-1, 31 and GLP-1 receptor agonists 32 inhibit NHE3 activity. Therefore, from a therapeutic point of view, DPPIV inhibition may improve the renal handing of sodium and water by increasing the GLP-1 bioactivity and inhibiting NHE3-mediated sodium reabsorption in the renal proximal tubule. This, in turn, may create a higher responsiveness to the renal actions of BNP in the distal nephron of patients with HF and experimental models. This hypothesis is corroborated by our findings that (1) sitagliptin-treated radiofrequency LV-ablated rats display a remarkable reduction in congestive HF parameters compared with LV-ablated rats not given sitagliptin; (2) the sitagliptintreated rats exhibit lower circulating total BNP but higher renal cortical protein kinase G activity than in the HF rats; and (3) renal cortical NHE3 protein expression is decreased by (46±4%, P<0.05) in sitagliptin-treated rats compared with HF rats ( Figure IIC in the online-only Data Supplement). Furthermore, DPPIV inhibition may directly increase the bioactivity of BNP (1-32) and potentiate its vascular and renal actions. In this regard, Gomez et al 26 discovered that acute intravenous administration of BNP (1-32) to sitagliptin-treated HF pigs improved cardiac performance and contractility, whereas no beneficial effect was observed when BNP (1-32) was administered to HF pigs treated with placebo. Moreover, we found that sitagliptin-treated rats display higher glomerular filtration rate than HF rats, which may be mediated through an increase in the active form of BNP. The assay we used to measure BNP does not distinguish among the several circulating molecular forms of BNP. Thus, further investigation will be necessary to address the question of whether DPPIV inhibition is capable of increasing the ratio of BNP to BNP in HF.
The stimulus that increases the circulating level and activity of DPPIV in HF remains to be determined. Unfortunately, few data are available regarding the origin of the soluble form of DPPIV. This phenomenon has been attributed to the proteolytic cleavage of DPPIV from the surface of peripheral lymphocytes, especially T lymphocytes, through an as yet unidentified sheddase. 1 Indeed, some reports have demonstrated that lymphocyte DPPIV expression is decreased in pathological conditions in which the serum DPPIV activity is elevated. 17, 33 Currently, one can only speculate that the sheddase that releases DPPIV from the cell surface to the blood stream is upregulated in HF as well as in other cardiovascular and metabolic diseases in which the serum DPPIV activity is higher than in healthy subjects.
